Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 1:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Drug 4 mL: Clear all
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Essential Oil-Based Product System for Digestive Support

NCT07653815
View directory record Official record
Conditions
Healthy
Interventions
essential oil supplement, Essential Oil, Placebo supplement, placebo essential oil
Dietary Supplement · Other
Lead sponsor
dōTERRA International
Industry
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Pleasant Grove, Utah
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 24, 2026, 1:29 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines

NCT04889209
View directory record Official record
Conditions
COVID-19
Interventions
Ad26.COV2.S, BNT162b2, mRNA-1273, mRNA-1273.211, mRNA-1273.222, SARS-CoV-2 rS/M1
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
867 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
10
States / cities
Decatur, Georgia • Baltimore, Maryland • New York, New York + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2025 · Synced Sep 24, 2026, 1:29 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Vaginal Estriol in Multiple Sclerosis

NCT03774407
View directory record Official record
Conditions
Multiple Sclerosis, Neurogenic Bladder
Interventions
vaginal estriol
Drug
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Sep 20, 2022 · Synced Sep 24, 2026, 1:29 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Incidence of Headache Following an Unintentional Dural Puncture

NCT01977898
View directory record Official record
Conditions
Postdural Puncture Headache, Post-Lumbar Puncture Headache, Cerebrospinal Fluid Leaks
Interventions
Morphine, Saline
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Sep 24, 2026, 1:29 PM EDT
Completed No phase listed Observational Results available

A Comparison of Ropivacaine Alone Versus Combination of Dexamethasone and Clonidine for Block

NCT02151487
View directory record Official record
Conditions
Upper Extremity Surgery
Interventions
Ropivacaine, Ropivacaine and dexamethasone, Ropivacaine and clonidine, Ropivacaine, dexamethasone and clonidine
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 4, 2019 · Synced Sep 24, 2026, 1:29 PM EDT
Completed Phase 2 Interventional Results available

Custodiol-HTK (Histidine-tryptophan-ketoglutarate) Solution as a Cardioplegic Agent

NCT01681095
View directory record Official record
Conditions
Coronary Artery Disease, Myocardial Ischemia, Coronary Disease, Heart Diseases, Valvular Heart Disease
Interventions
Custodiol HTK, Cold Blood Cardioplegia
Drug
Lead sponsor
Marc Sakwa, MD
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 5, 2019 · Synced Sep 24, 2026, 1:29 PM EDT
Completed Phase 2 Interventional Results available

Texan Allergy & Sinus Center Mountain Cedar Intra-Lymphatic Immunotherapy Study

NCT03682965
View directory record Official record
Conditions
Allergic Rhinitis Due to Tree Pollen, Allergic Conjunctivitis, Allergic Rhinoconjunctivitis
Interventions
Intra-lymphatic allergenic extract, Intra-lymphatic placebo
Biological
Lead sponsor
Christopher Thompson, MD
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Austin, Texas • Grapevine, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 19, 2021 · Synced Sep 24, 2026, 1:29 PM EDT
Completed Phase 2 Interventional

Pharmacokinetics and Safety Study of Tapentadol for Postsurgical Pain in Children and Adolescents

NCT01134536
View directory record Official record
Conditions
Pain, Postoperative, Postoperative Pain
Interventions
Tapentadol (OS) Oral Solution
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
6 Years to 17 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
10
States / cities
Little Rock, Arkansas • Washington D.C., District of Columbia • Meridian, Idaho + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2014 · Synced Sep 24, 2026, 1:29 PM EDT
Completed Phase 3 Interventional Results available

Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD)

NCT01825798
View directory record Official record
Conditions
Overweight, Autism Spectrum Disorder
Interventions
Metformin, Placebo
Drug
Lead sponsor
Holland Bloorview Kids Rehabilitation Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
3
States / cities
Columbus, Ohio • Pittsburgh, Pennsylvania • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Sep 24, 2026, 1:29 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Effects of Crofelemer on the Gut Microbiome in Healthy Volunteers and in HIV+ Patients With Non-Infectious Diarrhea

NCT04192487
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, Healthy Volunteers, HIV/AIDS, HIV Diarrhea, Human Immunodeficiency Virus
Interventions
Crofelemer delayed-release tablets 125mg
Drug
Lead sponsor
Napo Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
3
States / cities
Tustin, California • Stratford, Connecticut • Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 21, 2021 · Synced Sep 24, 2026, 1:29 PM EDT
Completed Phase 2Phase 3 Interventional

Efficacy and Safety Study Comparing Lorazepam and Diazepam for Children in the Emergency Department With Seizures (Status 2)

NCT00621478
View directory record Official record
Conditions
Status Epilepticus
Interventions
lorazepam or diazepam
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
3 Months to 18 Years
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
12
States / cities
Davis, California • Aurora, Colorado • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2012 · Synced Sep 24, 2026, 1:29 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Raxibacumab on Immunogenicity of Anthrax Vaccine Adsorbed

NCT02339155
View directory record Official record
Conditions
Infections, Bacterial
Interventions
AVA, Raxibacumab, Diphenhydramine
Biological · Drug
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 65 Years
Enrollment
573 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
3
States / cities
Edgewater, Florida • Overland Park, Kansas • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 17, 2024 · Synced Sep 24, 2026, 1:29 PM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Platelet Rich Plasma Injections In Young And Old Human Subjects

NCT06451120
View directory record Official record
Conditions
Osteoarthritis, Articular Cartilage, Musculoskeletal Disorders
Interventions
Platelet-Rich Plasma (PRP) Injections, Centrifuge, Control saline injection
Drug · Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 24, 2026, 1:29 PM EDT
Withdrawn Phase 2 Interventional

HIPEC as Neoadjuvant Treatment for Resectable Pancreatic Adenocarcinoma

NCT02850874
View directory record Official record
Conditions
Pancreatic Neoplasms, Pancreatic Adenocarcinoma
Interventions
Hyperthermic intraperitoneal chemotherapy, Open pancreaticoduodenectomy, Gemcitabine
Procedure · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 26, 2022 · Synced Sep 24, 2026, 1:29 PM EDT
Completed Phase 4 Interventional Results available

Semaglutide Treatment, Appetite, and Eating Behavior: Long-term Effects

NCT05548647
View directory record Official record
Conditions
Obesity
Interventions
Behavioral Treatment, Placebo, Semaglutide 2.4 MG/0.75 ML Subcutaneous Solution [WEGOVY]
Behavioral · Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 70 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 24, 2026, 1:29 PM EDT
Completed Phase 4 Interventional Results available

Adenosine Contrast CorrELations in Evaluating RevAscularizaTION

NCT03557385
View directory record Official record
Conditions
Percutaneous Coronary Intervention
Interventions
Iopamidol, adenosine, Navvus® Catheter, CVi® Contrast Delivery System
Drug · Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
5
States / cities
Long Beach, California • Coon Rapids, Minnesota • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2024 · Synced Sep 24, 2026, 1:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Affective Content on Drug Induced Amnesia of Episodic Memory

NCT00142493
View directory record Official record
Conditions
Memory Losses, Amnesia-Memory Loss
Interventions
Propofol, Thiopental Sodium, Dexmedetomidine Hydrochloride, Midazolam Hydrochloride, placebo
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 50 Years
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 23, 2015 · Synced Sep 24, 2026, 1:29 PM EDT
Terminated Phase 2 Interventional Results available

A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma

NCT01378871
View directory record Official record
Conditions
Adult T Cell Leukemia, Adult T Cell Lymphoma
Interventions
IMTOX-25
Drug
Lead sponsor
Amit Verma
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
7
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Sep 24, 2026, 1:29 PM EDT
Completed Phase 3 Interventional Results available

Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)

NCT01599806
View directory record Official record
Conditions
Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis
Interventions
Ceftazidime - Avibactam ( CAZ-AVI), Doripenem, Either switch to oral therapy: 500 mg of Ciprofloxacin (oral), or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 90 Years
Enrollment
641 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Detroit, Michigan • St Louis, Missouri • Indiana, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Sep 24, 2026, 1:29 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

A Study of the Functional Magnetic Resonance Imaging Response to Leptin and Pramlintide

NCT00691158
View directory record Official record
Conditions
Obesity
Interventions
Pramlintide (Amylin), Placebo (Normal Saline), 2 Metreleptin, Leptin plus Pramlintide
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 45 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 15, 2022 · Synced Sep 24, 2026, 1:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Pharmacodynamic Effects of a Single Oral Dose of GS-0976 (NDI-010976) in Healthy Adult Subjects

NCT02876796
View directory record Official record
Conditions
PD Effects of GS-0976 (NDI-010976) on Fractional DNL
Interventions
GS-0976, Placebo, 1-13C acetate, Fructose solution
Drug · Other
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 23, 2016 · Synced Sep 24, 2026, 1:29 PM EDT
Completed Phase 2 Interventional Results available

Furoscix in Heart Failure Patients With Diuretic Resistance

NCT05528588
View directory record Official record
Conditions
Heart Failure
Interventions
Furoscix, Diuretic Therapy
Combination Product · Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Sep 24, 2026, 1:29 PM EDT
Terminated Phase 3 Interventional Results available

The Safety and Tolerability of Budesonide Foam in Participants With Active Ulcerative Proctitis or Proctosigmoiditis

NCT01349673
View directory record Official record
Conditions
Proctitis, Proctosigmoiditis
Interventions
Budesonide Foam
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Sep 24, 2026, 1:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Effects of Omeprazole on the Pharmacokinetics of XS004 (Dasatinib) Tablets in Healthy Adult Subjects Under Fasting Conditions

NCT05433896
View directory record Official record
Conditions
Pharmacokinetics, Drug Interactions
Interventions
Dasatinib ASD, Omeprazole 40 MG
Drug
Lead sponsor
Xspray Pharma AB
Industry
Eligibility
18 Years to 60 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Dilworth, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 26, 2022 · Synced Sep 24, 2026, 1:29 PM EDT